Celcuity Inc.

Stocks

Market Closed - Nasdaq 23:00:00 28/08/2026 +03			5-day change	1st Jan Change
88.44 ^USD	-5.15%		-5.44%	-11.33%

08-26	Celcuity Inc Submits Supplemental New Drug Application to Fda for Revtorpyk (Gedatolisib) for Hr+/Her2-, Pik3ca Mutant Locally Advanced or Metastatic Breast Cancer	CI
08-26	Celcuity Submits Supplemental NDA for REVTORPYK in PIK3CA-Mutant Breast Cancer	MT

Published on 06/02/2026 at 06:40 pm +03 - Modified on 06/11/2026 at 04:25 pm +03

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the Celcuity VIKTORIA-1 Trial call. [Operator Instructions] Please be advised that today's

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

08-26	Celcuity Inc Submits Supplemental New Drug Application to Fda for Revtorpyk (Gedatolisib) for Hr+/Her2-, Pik3ca Mutant Locally Advanced or Metastatic Breast Cancer	CI
08-26	Celcuity Submits Supplemental NDA for REVTORPYK in PIK3CA-Mutant Breast Cancer	MT
08-14	Celcuity Inc., Q2 2026 Earnings Call, Aug 13, 2026
08-13	Celcuity Q2 Adjusted Loss Widens	MT
08-13	Earnings Flash (CELC) Celcuity Inc. Posts Q2 Adjusted Loss $1.07 per Share, vs. FactSet Est of $-1.12	MT
08-13	Celcuity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-30	Celcuity Announces FDA Approval And NCCN Guidelines Inclusion For REVTORPYK In Combination With Fulvestrant With Or Without Palbociclib	CI
07-15	Celcuity Inc. - Special Call
07-15	Celcuity shares fall as launch delay eclipses US approval for breast cancer drug	RE
07-15	Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval	RE
07-15	Celcuity Gets FDA Approval for Breast Cancer Drug	DJ
07-15	Celcuity's REVTORPYK Gets FDA Approval for HR+/HER2- Breast Cancer	MT
07-14	Celcuity Announces FDA Approval of REVTORPYK? (Gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer	CI
07-14	Correction to Celcuity Gets FDA Approval Headline	DJ
07-14	US FDA approves Celcuity's breast cancer drug	RE

Duration

Period

Sector